Analysis Genomic Vision Société Anonyme (0QT4)
6/2/2024
Analysis of Genomic Vision Société Anonyme (0QT4)
Genomic Vision Société Anonyme (symbol: 0QT4) has shown a downward trend in its stock price over the past few months. The Relative Strength Index (RSI) values have been consistently low, indicating oversold conditions. The Moving Average Convergence Divergence (MACD) indicator has not been providing clear signals, as the values are not available for some data points.The stock price has been fluctuating within a certain range, with occasional spikes in price but overall remaining on a downward trajectory. The Moving Average (MA) indicators, such as Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA), have also been showing a downward trend.
Overall, based on the available data, Genomic Vision Société Anonyme appears to be facing challenges in terms of price performance and technical indicators. Investors may want to closely monitor the stock for any potential changes in trend or signals that could indicate a reversal in the current downward trajectory.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for October 31, 2024, were not provided at the time. On August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic 🧠
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price has fluctuated between a fifty-two-week low and high, with a positive change over the period.
Valuation metrics show a relatively high PEG ratio and price-to-book ratio, while the forward and trailing P/E ratios are moderate. The company's market capitalization and enterprise value are substantial, with a reasonable price-to-sales ratio.
The stock price summary includes beta, moving averages, and the range of prices over the past fifty-two weeks.
Lastly, dividends and splits information reveals details about dividend rates, payout ratios, and historical split factors for the company's stock.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From the data provided, we can observe the following trends:
- The company experienced a decrease in sales from FY 2022 to FY 2023.
- There was a significant increase in sales from FY 2020 to FY 2021, followed by a slight decrease in FY 2022.
- Overall, there has been a general upward trend in sales over the past four fiscal years, with some fluctuations.
These revenue figures provide insights into the company's performance and can be used to analyze its growth and market position over the specified period.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is slightly higher at 5.2%.
3. Current Year: For the current year, the growth rate is estimated to be 7.6%.
4. Next Year: The growth rate is expected to increase to 9.7% for the next year.
5. Past 5 Years (per annum): Over the past 5 years, the company has shown a growth rate of approximately 20.1% per annum.
6. Next 5 Years (per annum): Looking ahead, analysts project a growth rate of around 9.7% per annum for the next 5 years.
Overall, the company is expected to experience a moderate growth rate in the near term, with a slightly higher growth rate anticipated for the next year. However, this growth rate is lower compared to the growth rate achieved in the past 5 years.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median and average price above the current price. However, there is a wide range between the low and high forecasts, indicating some uncertainty or differing opinions among analysts.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
6. The company has been relying more on non-current assets to support its operations.
7. There has been a consistent increase in shareholders' equity, indicating a positive trend in the company's financial health.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant cash outflows, mainly due to common stock repurchases and dividend payments.
6. Investing activities have also seen significant cash flows, with large amounts spent on the purchase and sale of investments.
7. The company has been managing its debt levels through debt issuances and payments.
8. Overall, the company's cash flow statement reflects a mix of operational, financing, and investing activities that impact its financial health and liquidity position.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average EPS estimate is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous year.
4. For the next year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a growth trajectory from the EPS of $6.10 in the current year.
Overall, the analysts' estimates point towards a positive outlook for the company's earnings per share, showing a trend of expected growth in both the short term and the long term.
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
